All In Biotech

Drug Trial Radar · NCT07010406

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

A Phase 1, Open-label, Randomized, 2-part Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Jun 6, 2025

Primary completion

Aug 19, 2025

Study completion Aug 19, 2025

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Jun 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the relative bioavailability of Povetacicept formulations, bioequivalence of Povetacicept presentations, and safety and tolerability of Povetacicept.

Conditions

  • Healthy Volunteers

Interventions

  • PovetaciceptDrug

    Injection for Subcutaneous Administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration Versus Time Curve From the Time of Dosing to 28 Days (AUC0-28d) of Free PovetaciceptTime frame: From Day 1 up to Day 30
  2. Maximum Observed Plasma Concentration (Cmax) of Free PovetaciceptTime frame: From Day 1 up to Day 30

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Celerion - Tempe

    Tempe, Arizona

  • Celerion - Lincoln

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.